Botulinum toxin – I shouldn’t look surprised but…
Posted in Announcement, News
The BBC reports today about the supply of botulinum toxin to patients and beauty clinics. Sadly, these supplies are reportedly from qualified and unqualified practitioners. The secondary care spend for these medicines is nearing £50m a year with an average annual growth and spend over the last 5 years of 14%.
For those within the NHS that have access to Define you can see these changes at product level Report – Define Reports
Diversion of stocks
Botulinum toxins are one of the specific medications that are available to organisations to monitor in the Abusable Drugs Investigational System (ADIoS). The following links will give you an effective picture, updated daily, of what is happening in your organisation for these medications.
ADIoS system links below (requires an ADIoS license):
- Type A
- Botulinum toxin type A 50unit powder for solution for injection vials – ADIoS
- Botulinum toxin type A 100unit powder for solution for injection vials – ADIoS
- Botulinum toxin type A 500unit powder for solution for injection vials – ADIoS
- Botulinum toxin type A 200unit powder for solution for injection vials – ADIoS
- Botulinum toxin type A 300unit powder for solution for injection vials – ADIoS
- Type B
ADIoS looks for abnormal patterns of issue for controlled drugs and other specific medications with abuse potential and is used regularly in over 100 NHS hospitals to provide assurance in monitoring for the Controlled Drugs Accountable Officer.